Aktis Oncology’s (NASDAQ:AKTS) Quiet Period Set To End Tomorrow

Aktis Oncology’s (NASDAQ:AKTS) quiet period will end on Wednesday, February 18th. Aktis Oncology had issued 17,650,000 shares in its public offering on January 9th. The total size of the offering was $317,700,000 based on an initial share price of $18.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. TD Cowen started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. JPMorgan Chase & Co. began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price objective for the company. Leerink Partners initiated coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective on the stock. Bank of America initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price for the company. Finally, Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.67.

Aktis Oncology Stock Down 0.8%

Shares of AKTS opened at $17.76 on Tuesday. Aktis Oncology has a 1 year low of $16.80 and a 1 year high of $29.16.

Insider Activity at Aktis Oncology

In other news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the insider owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. This trade represents a 17.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the transaction, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. This represents a 12.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 6,117,776 shares of company stock valued at $110,119,968.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.